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Abstract
Purpose Aldo-keto reductases (including AKR1B1 and
AKR1B10) constitute a family of oxidoreductases that have
been implicated in the pathophysiology of diabetes and can-
cer, including colorectal cancer (CRC). Available data indicate
that, despite their similarities in structure and enzymatic func-
tions, their roles in CRC may be divergent. Here, we aimed to
determine the expression and functional implications of
AKR1B1 and AKR1B10 in CRC.
Methods AKR1B1 and AKR1B10 gene expression levels
were analyzed using publicly available microarray data and
ex vivo CRC-derived cDNA samples. Gene Set Enrichment
Analysis (GSEA), The Cancer Genome Atlas (TCGA) RNA-
seq data and The Cancer Proteome Atlas (TCPA) proteome
data were analyzed to determine the effect of high and low
AKR1B1 and AKR1B10 expression levels in CRC patients.
Proliferation, cell cycle progression, cellular motility, adhe-
sion and inflammation were determined in CRC-derived cell
lines in which these genes were either exogenously
overexpressed or silenced.
Results We found that the expression of AKR1B1 was unal-
tered, whereas that of AKR1B10 was decreased in primary
CRCs. GSEA revealed that, while high AKR1B1 expression
was associated with increased cell cycle progression, cellular
motility and inflammation, high AKR1B10 expression was
associated with a weak inflammatory phenotype. Functional
studies carried out in CRC-derived cell lines confirmed these
data. Microarray data analysis indicated that high expression
levels of AKR1B1 and AKR1B10 were significantly associat-
ed with shorter and longer disease-free survival rates, respec-
tively. A combined gene expression signature of AKR1B10
(low) and AKR1B1 (high) showed a better prognostic stratifi-
cation of CRC patients independent of confounding factors.
Conclusions Despite their similarities, the expression levels
and functions of AKR1B1 and AKR1B10 are highly diver-
gent in CRC, and they may have prognostic implications.
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1 Introduction
Recent studies have indicated that the incidences of diabetes
and cancer are closely related in many (but not all) countries
worldwide [1, 2] and that glucose sensitizing drugs can pro-
vide significant protection from the development of colorectal
cancer (CRC) [3]. Therefore, an evaluation of signaling path-
ways that may be affected in both diabetes and CRC is war-
ranted. The aldo-keto reductases (AKRs) constitute a large
family of oxidoreductases that can catalyze reduction reac-
tions in the presence of nicotinamide adenine dinucleotide
(phosphate) (NAD(P)H) [4]. AKRs, most commonly
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AKR1B1, are involved in the first step of the polyol pathway,
where conversion of glucose into sorbitol takes place using
NAD(P)H as cofactor. As such, this enzyme has been found to
be implicated in the pathophysiology of diabetes [5].
AKR1B10 only weakly reduces glucose, but has been found
to be implicated in the metabolism of compounds such as 4-
hydroxynonenal, acrolein, retinals and phospholipid alde-
hydes [6]. These compounds can also be reduced by
AKR1B1 [6]. AKRs have also been found to be involved in
the reduction of lipid peroxidation-derived aldehydes and
their corresponding glutathione conjugates [7]. These reduced
compounds serve as inflammatory signals, which mediate re-
active oxygen species (ROS)-related signaling and lead to
inflammatory responses [8]. Inflammation has been found to
be strongly implicated in the development of CRC [9] and
inhibition of the ubiquitously expressed AKR protein
AKR1B1 with fidarestat has been found to inhibit inflamma-
tion in CRC [10]. Additionally, siRNA-mediated silencing of
AKR1B1 in the colon cancer-derived cell line SW480 was
found to inhibit tumor growth in a nude mouse xenograft
model [11]. AKR1B1 inhibition with fidarestat has been
shown to reduce the expression of the oncogenic microRNA
miR-21, leading to upregulation of the tumor suppressor pro-
teins PTEN [12] and PCDC4 [13] in CRC.
Data on the role of AKR1B10 in CRC is relatively limited.
AKR1B10 is abundantly expressed in non-transformed small
intestine and colon, while a lower expression has been ob-
served in various other organs such as liver, prostate, thymus,
testis and skeletal muscle [14]. A significant decrease in the
expression of AKR1B10 has been reported for CRCs and
adenomas compared to their corresponding normal tissues
[15]. Additionally, AKR1B10 has been reported to serve as
a direct transcriptional target of p53 and to participate in p53-
mediated apoptosis [15]. AKR1B10 can also metabolize elec-
trophilic carbonyl compounds to harmless intermediates and,
thereby, protect CRC cells from DNA damage [16].
Thus, in spite of the high similarities in structures and enzy-
matic activities of AKR1B1 and AKR1B10, the expression
levels and functions of the two proteins in CRC appear to be
divergent. So far, however, a systematic functional comparison
of the two proteins in CRC has not been carried out. Here, we
have experimentally established a complete divergence in acti-
vation of inflammatory signaling and cellular motility of the
two proteins. Gene set enrichment analysis (GSEA) using a
publicly available microarray dataset as well as The Cancer
Genome Atlas (TCGA) and The Cancer Proteome Atlas
(TCPA) data analyses for tumors with high and low AKR1B1
expression levels or high and low AKR1B10 expression levels
confirmed these findings. AKR1B1 expression was also found
to be associated with oncogenic characteristics, since silencing
of the corresponding gene led to reduced cell proliferation and a
slower cell cycle progression. Additionally, multivariate Cox
proportional hazards regression analysis revealed that a
combination of high AKR1B10 expression and low AKR1B1
expression was of prognostic significance, i.e., it was signifi-
cantly associated with a longer disease-free survival of CRC
patients, independent of confounding factors.
2 Materials and methods
2.1 Cell culture and transfection
HCT-116 cells were purchased from the Deutsche Sammlung
von Mikroorganismen und Zellkul turen (DSMZ,
Braunschweig, Germany) and HT-29 cells from ŞAP
Enstitüsü, Ankara, Turkey. SW480, RKO, Caco-2 and LoVo
cells were purchased from the ATCC (Middlesex, UK). All cell
lines were cultured under ATCC-specified conditions in a hu-
midified incubator with 5% CO2 at 37 °C. All cell culture
consumables were purchased from Biochrom AG, Germany.
Normal colon RNA was purchased from Origene (Rockville,
MD, USA).
AKR1B1 expression was knocked down in HCT-116 cells
using a SureSilencing shRNA plasmid kit (Catalog no:
KH02359, Qiagen, Germany). A pool of 4 shRNA vectors
was transfected into ~70% confluent HCT-116 cells in
OptiMEM (Thermo Fischer Scientific, USA) using X-
tremegene HP at a 1:2 ratio (1 μg vector:2 μl of X-
tremegene HP) according to the manufacturer’s protocol.
Transfected cells were selected using 500 μg/ml G418
(Roche, Switzerland) for 3–4 weeks after which two clonal
lines with a stable knockdown of AKR1B1were chosen for
further experiments. As a control, cells stably transfected with
a scrambled control vector as provided in the kit was used.
The cells were maintained in 225 μg/ml G418. All experi-
ments with stably transfected cells were carried out within
the 8th passage. For exogenous overexpression of AKR1B1,
a pCMV6-AC mammalian expression vector was used
(Origene). Cells were transfected at 70% confluency using
X-tremegene HP at 1:2 ratio of plasmid to transfection re-
agent. After 24 h the cells were harvested and processed for
protein or RNA isolation. Where indicated, rescue experi-
ments were carried out by overexpressing AKR1B1 in
AKR1B1 silenced cells (shB1_Clone 1).
AKR1B10 cDNA, cloned into a pCOLD1 vector, was ob-
tained as a gift from Dr. Satoshi Endo, Gifu Pharmaceutical
University, Japan [6]. The AKR1B10 cDNA insert was ex-
cised using NheI and EcoRI and sub-cloned into a pcDNA3.1
vector using the same restriction sites. Correct insertion was
confirmed by sequencing. For exogenous overexpression,
HCT-116 cells were transfected at 70% confluency using X-
tremegene HP at 1:1 ratio of plasmid to transfection reagent.
After 24 h the cells were harvested and processed for protein
or RNA isolation. All transient overexpression and silencing
experiments were confirmed by Western blotting.
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2.2 Protein isolation and Western blotting
Total protein was isolated using aM-PERMammalian Protein
Extraction Reagent (Thermo Fisher Scientific, USA) contain-
ing protease and phosphatase inhibitors (Roche, Germany)
according to the manufacturer’s instructions. For the isolation
of cytoplasmic and nuclear proteins cells were collected,
washed with PBS and resuspended in hypotonic buffer
(100 mM HEPES pH:7.5, 40 mM NaF, 100 μM Na2MoO4
and 1 mM EDTA). Next, the cells were transferred to pre-
chilled eppendorf tubes and incubated on ice for 15 min.
Then, 40 μl of 10% NP-40 was added and mixed, after which
the tubes were centrifuged. The supernatant was carefully col-
lected as cytoplasmic fraction. Next, the pellets were resus-
pended in nuclear extraction buffer (20 mM HEPES pH:7.9,
0.2 mM EDTA, 3 mMMgCl2, 840 mM NaCl, 20% glycerol)
by shaking for 30 min in an orbital shaker with vortexing
every 15 min. The resulting suspension was centrifuged at
14000×g for 10 min at 4 °C after which the supernatants were
transferred to fresh eppendorf tubes as nuclear fraction. The
amounts of proteins were measured using a Coomassie
Protein Assay Reagent (Thermo Fisher Scientific, USA) and
determined relative to a standard curve generated with bovine
serum albumin. For subsequent Western blotting 30–50 μg of
proteins from each sample were separated in 10% SDS- poly-
acrylamide gels and transferred to polyvinylidene fluoride
(PVDF) membranes. Western blotting was carried out using
standard protocols. Visualization of the bands was performed
using a Clarity ECL Substrate (Bio-Rad, USA) and imaged on
a Chemi-Doc MP system (Bio-Rad). The membranes were
also incubated with anti-β-Actin or anti-GAPDH antibodies
to ensure equal protein loading. Details on the antibodies used
and their dilutions are provided in Supplementary Table 1.
2.3 cDNA synthesis and qRT-PCR
Total RNAwas isolation using a RNeasy RNA Extraction Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
guidelines. The RNA was treated with DNAse I (Thermo
Scientific) to remove genomic DNA, after which 1 μg RNA
was converted to cDNA using a RevertAid First Strand cDNA
Synthesis Kit (Thermo Scientific). qRT-PCR reactions were
carried out in a Rotor GeneQ 6000 system (Qiagen) according
to the manufacturer’s instructions. Fold changes were calcu-
lated relative to an internal control (β-Actin) using the Pfaffl
method [17].MIQE guidelines were followed in the qRT-PCR
reactions [18]. The primer sequences are listed in
Supplementary Table 1.
2.4 Proliferation assays
To determine the effect of AKR1B1 expression knockdown
on cell proliferation a BrdU incorporation assay was used. To
this end, 10,000 cells were seeded per well in a 96-well plate
and allowed to attach for 24 h. Next, the cells were incubated
with serum-free medium overnight for synchronization [19],
after which complete mediumwas added and at 0, 24 and 48 h
the medium was removed followed by a BrdU assay accord-
ing to the manufacturer’s instructions (Roche). Measurements
were performed using a microplate reader (Thermo Fisher
Scientific) at 370 nmwithin 5–15min. To determine the effect
of exogenous AKR1B10 overexpression, a Trypan blue ex-
clusion assay followed by cell counting was carried out.
Twenty-four hours after transfection, the cells were collected
and mixed with a 0.4% Trypan Blue solution (Bio Rad) after
which the cells were counted in a TC20™ Automated Cell
Counter (Bio Rad).
2.5 Cell cycle assay
To determine the effects of AKR1B1 expression knockdown
or exogenous AKR1B10 overexpression on cell cycle pro-
gression, the cells were synchronized overnight in serum free
medium. Next, at 0 and 6–8 h for AKR1B1 knockdown and
24 h for AKR1B10 overexpression, the cells were collected
and fixed through a drop-wise addition of 70% ice-cold etha-
nol and kept at -20 °C for at least 2 h. Next, the fixed cells
were washed in PBS, resuspended in a staining solution
consisting of 0.1% Triton X-100, 2 mg/ml RNase A (DNase
free) and 20 μg/ml Propidium Ioide (Sigma-Aldrich, USA)
and incubated for 30 min in the dark at room temperature.
The percentages of cells in different stages of the cell cycle
were determined using the FL-3 channel of an Accuri C6
Flow Cytometer (BD Biosciences, USA) and compared with
scrambled or empty vector controls.
2.6 Luciferase assay
In order to determine the effects of AKR1B1 and AKR1B10
on the transcriptional activity of NF-κB, a Pathdetect reporter
plasmid (Agilent Genomics, USA), which contains 5 copies
of the binding sites for NF-κB upstream of a firefly gene, was
used. A pRL-TK Renilla plasmid (Promega, USA) was used
as an internal control. 50,000 cells per well were seeded and
allowed to attach in 48 well-plates. Next, the cells were
transfected with a 1:250 ratio of Firefly:Renilla vectors for
24 h, harvested and assayed using a Dual-Glo Luciferase
Assay Kit (Promega, USA) according to manufacturer’s
guidelines in conjunction with the use of opaque 96-well
plates in a luminometer (Turner Biosystems, USA).
2.7 Determination of ROS levels
To determine whether AKR1B1 or AKR1B10 expression
modification alters the level of reactive oxygen species
(ROS) production, a nitro-blue tetrazolium (NBT) assay
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was carried out. NBT is a soluble nitro-substituted aromat-
ic tetrazolium compound that forms formazan crystals in
the presence of cellular superoxide ions that can subse-
quently be measured colorimetrically. HCT-116 cells with
a stable knockdown of AKR1B1 expression were seeded in
96-well plates (1 × 104 cells/well). 24 h after seeding, the
cells were incubated with NBT solution (2 mg/ml for each
well) for 5 h at 37 °C. Then, the cells were fixed with 100%
methanol for 5 min and air dried at room temperature. The
blue formazan crystals that were formed were solubilized
in 120 μl KOH and 140 μl DMSO by thorough pipetting.
The absorbance was read colorimetrically at 620 nm in a
microplate reader.
2.8 In vitro scratch wound healing assay
To determine the effect of AKR1B1 and AKR1B10 expres-
sion on cellular motility, a scratch wound healing assay was
carried out as described previously [20]. Briefly, stably
transfected cells were seeded to 80% confluency. Next,
scratch wounds were made in the respective plates using a
sterile 100 μl-pipette tip. Cell debris was removed by washing
the cells twice with cell culture grade PBS. Then, the cells
were incubated in complete medium containing 0.5 μMmito-
mycin C [21] to prevent any cell proliferation and at 0, 24 and
48 h time points, the cell images were captured using a JuLi
Smart Fluorescent Cell Imager. Medium containing 0.5 μM
mitomycin C was refreshed after 24 h. The width of the
wounds at each time point was measured using a ruler.
2.9 Transwell migration assay
In order to assess the effects of AKR1B1 or AKR1B10
expression on cellular migration, a Transwell migration as-
say was carried out. To this end, the cells were starved
overnight, washed twice and resuspended in medium con-
taining 1% FBS. Then, the cells were counted using a he-
mocytometer and ~5 × 104 cells in a 100 μl suspension were
seeded on Transwell chambers containing membranes with
8 μm pores (ThinCert™ Cell Culture Inserts, Greiner Bio-
One, Germany). At the same time, the lower chamber was
filled with complete medium (10% FBS). The cells were
allowed to migrate for 48 h after which the Transwells were
taken out and non-migrated cells were removed with sterile
cotton swabs. This latter step was repeated at least twice.
Next, the Transwells were fixed in 100% methanol for
10 min, stained with Giemsa solution (Merck Millipore,
USA) for 2 min at room temperature, and washed with
sterile distilled water extensively in order to remove all
excess dye. Finally, the Transwells were left to air dry in-
side a fume hood. When the Transwell filters were
completely dried, the membranes were cut out with a
bistoury and mounted on a glass slide with a drop of
immersion oil. The total number of cells was counted at
20× magnification under an inverted light microscope
(Leica, Germany).
2.10 Collagen deposition assay
To determine whether AKR1B1 expression knockdown alters
cellular motility through collagen deposition, a Sirius red assay
was carried out. Briefly, stably AKR1B1silenced HCT-116 cells
(5 × 105) were seeded in 12-well plates. 24 h after seeding, the
cells were washed once with cell culture grade PBS and then
fixed in Bouin’s fluid (prepared as mixture of 15 ml saturated
picric acid, 5 ml 37% formaldehyde and 1 ml glacial acetic acid)
for 1 h. Next, the wells were rinsed 3× in PBS for 15 min, after
which the plates were air-dried and stained with 0.5 ml of
100 mg/ml Sirius Red (Sigma-Aldrich) dissolved in saturated
picric acid for 1 h with mild shaking. Subsequently, the dye
was removed and the wells were rinsed with 0.01 M HCl to
remove the excess dye. The deposited collagen, which stains
red, was visualized under an inverted light microscope.
2.11 Hanging drop assay
A hanging drop assay was carried out to determine whether
exogenous AKR1B1 overexpression results in alterations in
cell-cell adhesion as described previously [20]. Briefly, HCT-
116 cells were transfected with 1 or 2 μg AKR1B1 expression
vector or its corresponding empty vector for 24 h and collect-
ed. Drops of these cells (30 μl, 2 × 106 cells/ml) were pipetted
on the inner surface of the lid of a sterile low attachment Petri
dish after which the lid was placed on the petri dish and the
now ‘hanging drops’ were incubated for 48 h in a cell culture
incubator. Next, the drops were pipetted onto glass slides,
covered with coverslips and imaged. At least 20–30 aggre-
gates were photographed for each transfection.
2.12 In silico analyses
Gene expression data of tumor datasets were downloaded
from Gene Expression Omnibus (GEO) (http://www.ncbi.
nlm.nih.gov/geo) and RMA normalized using BRB-array
tools (https://brb.nci.nih.gov/BRB-ArrayTools/). Clinical
data related to the GSE39582 dataset (n = 585) were
obtained from Marisa et al. [22]. Log expression values of
AKR1B1 and AK1B10 were determined and plotted. To
determine correlations between AKR1B1 or AKR1B10
expression and that of pro-inflammatory genes, Level3
RNA-seq and RPPA (reverse phase protein array)-based ex-
pression data of 132 primary CRC tissues were downloaded
from The Cancer Genome Atlas (TCGA) data portal
(cancergenome.nih.gov). Linear correlation (Spearman) anal-
yses between AKR1B1 and AKR1B10 expression and a set of
pro-inflammatory genes were performed. Tumor samples
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from TCGA were independently ranked according to
RNAseq-based AKR1B1 and AKR1B10 expression levels
and tumors with top 30% and bottom 30% expression were
analysed for each gene. Differential protein expression and
GSEA analysis between tumors within the top and bottom
30% were performed for both genes using the Broad
Institute’s desktop application (http://software.broadinstitute.
org/gsea/downloads.jsp) according to the corresponding
guidelines. Collapsing mode was used as maximum probe
and Gene Ontology Bc5 all^ was used as genesets database.
2.13 Determination of AKR1B1 and AKR1B10 expression
in primary CRC samples
Twenty six annotated first-strand cDNA samples (6-normal,
4-stage I, 8-stage II, 4-stage IIIB and 4-stage IV) from the
Human Tissue Scan Colon Cancer Tissue qPCR Panel IV,
HCRT304 (Origene, USA), were diluted 1:10 after which rel-
ative AKR1B1 and AKR1B10 mRNA levels were measured
by qRT-PCR using a CFX Connect Real-Time PCR Detection
System (BioRad, USA). Cycle threshold (Ct) values of indi-
vidual genes were subtracted from Ct values for the reference
gene β-Actin (ΔCt), and subsequently used to calculate fold
changes in relative gene expression levels (2–ΔΔCT) relative
to one of the normal samples. The primer sequences used are
listed in Supplementary Table 1.
2.14 Statistical analyses
All experiments were carried out as 2 or 3 independent bio-
logical replicates, each with at least 3 technical replicates.
GraphPad Prism 6.1 (GraphPad Software Inc., USA) or
SPSS Statistics v.19 (IBM, 2010, Chicago, IL, USA) were
used for data analysis. One-way ANOVA, Student’s t test or
Mann Whitney U test were employed to determine signifi-
cance. Kaplan-Meier plots and the log-rank test were used to
compare the clinical outcomes among high-low expression
groups. Univariate and multivariate Cox proportional hazards
regression analysis was performed using SPSS Statistics v.19.
p < 0.05 was considered as statistically significant. Log-rank
tests using all cut-off values (LRMC) for a given dataset were
obtained using an in-house, R-based script [23]. Specific sta-
tistical analyses are further explained in the figure legends.
3 Results
3.1 AKR1B1 and AKR1B10 expression in primary
colorectal cancer samples and cell lines
To determine the expression of AKR1B1 and AKR1B10 in
primary colorectal cancer (CRC) samples, publicly avail-
able gene expression data (microarray-based dataset
GSE39582; n = 585) were downloaded from GEO. We
found that the expression of AKR1B10 was significantly
reduced in the CRC samples compared to normal samples,
irrespective of cancer stage (all cancer stages versus nor-
mal: p < 0.001) (Fig. 1A). In contrast, we found that the
expression of AKR1B1 showed no difference between the
CRC (all stages) and normal samples (p > 0.05). A signif-
icant decrease in the expression of AKR1B1 was, however,
observed in Stage 0 (carcinoma in situ) samples compared
to normal control samples (p < 0.0011). To confirm the
microarray-based expression data, we decided to determine
the AKR1B1 and AKR1B10 mRNA expression levels in
an independent set of CRC samples using qRT-PCR anal-
ysis. In concordance with the microarray-based data, we
observed a significant decrease in AKR1B10 expression
in the CRC samples compared to its respective normal
samples (Fig. 1B), especially at stages III and IV
(Supplementary Fig. 1A), whereas no significant changes
in AKR1B1 expression were observed between these sam-
ples (Fig. 1B) or stages (Supplementary Fig. 1B).
We next determined the expression of AKR1B1 and
AKR1B10 in several CRC-derived cell lines. Compared to
normal colon, the mRNA expression of AKR1B1 was found
to be higher in HCT-116 and Caco-2 cells and undetectable in
all other cell lines tested. On the other hand, we found that the
expression of AKR1B10 was relatively low in all cell lines
tested, except HT29 (Fig. 1C). Also at the protein level, we
found that AKR1B1 was expressed in HCT-116 and Caco-2
cells. An additional band appeared at a slightly higher molec-
ular weight in HT-29 cells. A protein BLAST of all AKR
family members revealed that AKR1B1 exhibits a 55% sim-
ilarity in amino acid sequence with AKR1CL2, a 68% simi-
larity with AKR1B15 and a 71% similarity with AKR1B10
(E.G.S. and S.B., unpublished data). Since we did not detect
any mRNA expression of AKR1B1 in these cells, we specu-
late that the band observed may correspond to another mem-
ber of the AKR family that is also recognized by the antibody
used. AKR1B10 was found to be expressed solely in HT-29
cells (Fig. 1C). Therefore, to determine whether the expres-
sion of AKR1B1 or AKR1B10 plays any role in CRC, we
separately silenced AKR1B1 and exogenously overexpressed
AKR1B10 inHCT-116 cells (Fig. 1D). As a control, AKR1B1
and AKR1B10 were exogenously overexpressed in LoVo
cells, which do not express any detectable levels of either
protein (Supplementary Fig. 1C).
3.2 AKR1B1, but not AKR1B10, affects cellular
proliferation and cell cycle progression
Using a BrdU incorporation assay, we found that AKR1B1
silencing resulted in a decrease in proliferation of HCT-116
cells (Fig. 2A). This observation was supported by a reduced
phosphorylation of ERK1/2, a mitogenic marker of the MAP
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kinase cascade, in cells grown in complete medium (Fig. 2C,
left panel). To assess the effect of AKR1B10 on cellular pro-
liferation, a Trypan blue exclusion assay followed by automat-
ed counting was carried out. No differences in cell numbers
were observed when AKR1B10 was exogenously
overexpressed in HCT-116, SW480 or LoVo cells (Fig. 2B),
along with no changes in ERK1/2 phosphorylation (Fig. 2C,
right panel).
To determine effect of AKR1B1 silencing on cell cycle
progression, PI staining followed by flow cytometry was
used. By doing so, we found that AKR1B1 silencing did
not lead to a cell cycle arrest. Rather, a slowing down of
the cell cycle was observed whereby a greater proportion
of AKR1B1 silenced cells was retained in the G1 phase
and entered the S phase later than in the scrambled control
cel ls a t 8 h (Fig. 2D, Supplementary Fig. 2A).
Interestingly, we observed increased Cyclin E protein
levels in starved (synchronized) and released (6–8 h) cells,
as well as in unsynchronized cells in which AKR1B1 was
silenced. However, when we determined the fold changes
in Cyclin E levels of starved versus released cells for both
AKR1B1 silenced and scrambled control cells, we ob-
served a statistically significant decrease in Cyclin E in
the AKR1B1 silenced cells 6-8 h after release. No differ-
ence was observed in Rb phosphorylation. Also, no differ-
ence in cell cycle progression was observed in exogenous-
l y AKR1B10 o v e r e x p r e s s i n g HCT- 11 6 c e l l s
(Supplementary Fig. 2B).
3.3 AKR1B1 enhances and AKR1B10 reduces cell motility
Gene Set Enrichment Analysis (GSEA) [24] of the
GSE39582 [22] dataset for the high 30% and low 30%
AKR1B1 expressing cases indicated a significant
(p < 0.001) enrichment in the Gene Ontology (GO) term
BCELL_SUBSTRATE_ JUNCTION^ in tumor samples
with a high AKR1B1 expression (Fig. 3A; for the full set
of genes for this GO term, see Supplementary Table 2).
The Cancer Proteome Atlas (TCPA) was used to mine data
from colon and rectal patient samples [25]. Differential
expression analysis of proteins between the AKR1B1 high
30% versus the AKR1B1 low 30% patients revealed a sig-
nificantly higher expression of the mesenchymal/motility
markers collagenVI (p = 0.0003), fibronectin (p = 0.0002)
and transglutaminase (p = 0.0019), whereas significantly
lower expression levels were seen for the junctional protein
claudin-7 (p = 0.0011), which has been associated with
epithelial characteristics [26], and FOXO 3a (p = 0.005),
a transcription factor that can enhance the expression of
antioxidant proteins [27] (Fig. 3B; for the full list of
significantly altered proteins see Supplementary Table 3).
None of these proteins was found to be significantly up-
regulated in AKR1B10 high expressing tumors (p > 0.05).
Therefore, we set out to test whether silencing of AKR1B1
or exogenous overexpression of AKR1B10 may result in
alterations in cell motility. We found that AKR1B1 si-
lenced cells (both clones tested) showed a significantly
slower closure in a wound healing assay (Fig. 3C and
Supplementary Fig. 3A), while a Transwell migration as-
say revealed a significantly lower amount of migrating
cells (Fig. 3D, left panel, Supplementary Fig. 3B). As the
exogenous overexpression of AKR1B10 was carried out
transiently, and we thus could not be sure that the cells at
the border of the wound in the scratch wound assay would
be expressing AKR1B10, we carried out a Transwell mi-
gration assay and found a significant decrease in cell mi-
gration when AKR1B10 was overexpressed (Fig. 3D, right
panel, Supplementary Fig. 3C).
CollagenVI was found to be highly expressed
(p = 0.0003) in the TCPA data set of samples with high
AKR1B1expression. Therefore, we carried out a collagen
deposition assay using Sirius Red staining on HCT-116
cells in which AKR1B1 was knocked down. We observed
a decrease in collagen deposition in cells in which
AKR1B1was stably silenced (Fig. 3E). To further sub-
stantiate the notion that alterations in cell-cell adhesion
in cells expressing AKR1B1 may lead to altered motility,
we exogenously overexpressed AKR1B1 in HCT-116
cells using increasing amounts of plasmids and carried
out a hanging drop assay. By doing so we found that,
while control cells formed large cell clusters indicating
good cell-cell contacts, AKR1B1 overexpressing cells
showed a clear decrease in the formation of compact cel-
lular aggregates (Fig. 3F). This effect was more pro-
nounced in cells that were transfected with the higher
amount of plasmid. Interestingly, we did not observe any
change in expression of well-known epithelial markers,
such as E-cadherin, or mesenchymal markers, such as
vimentin (data not shown).
Fig. 1 Expression of AKR1B1 and AKR1B10 in primary CRC
samples and CRC-derived cell lines. (A). Log2 AKR1B1 and
AK1B10 expression values from the GSE39582 dataset (n = 585) are
plotted. The horizontal lines indicate means. Statistical significance was
determined by Student’s t-test. No change in AKR1B1 expression and a
significant decrease in AKR1B10 expression was observed across stages
I-IV compared to normal samples. (B). qRT-PCR analysis of CRC cDNA
samples from a Tissue Scan array showing no difference in AKR1B1
expression and a reduction in AKR1B10 expression in CRC versus nor-
mal tissues. Statistical analysis was carried out using a non-parametric
Mann Whitney U test. (C). qRT-PCR and Western blot-based AKR1B1
and AKR1B10 expression analyses of a panel of CRC-derived cell lines.
(D). Western blot confirming the silencing of AKR1B1 (shB1 Clone 1
and shB1 Clone 2) and exogenous overexpression of AKR1B10 in HCT-
116 cells. ****p < 0.0001, **p < 0.01
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Fig. 2 Effect of AKR1B1 and AKR1B10 expression on cellular
proliferation and cell cycle progression. (A). BrdU incorporation
assay showing a decrease in proliferation in stably AKR1B1 silenced
HCT-116 cells. Statistical analyses were carried out with ANOVA using
Tukey’s posthoc test. (B). Trypan blue exclusion assay showing absence
of change in proliferation in HCT-116, SW-480 and LoVo cells transiently
transfected with an AKR1B10 expression plasmid. (C). Western blot
showing that AKR1B1 silencing leads to a decrease in EKR1/2 protein
activation, whereas exogenous AKR1B10 overexpression did not result
in any alteration. Numbers under the bands indicate band intensities nor-
malized to the loading control. (D). Cell cycle distribution of serum
starvation-synchronized AKR1B1 silenced cells collected at 0 and 8 h
after release from starvation. The average cell cycle distributions (three
independent experiments) of scrambled control and shB1 Clone1 (unsyn-
chronized or synchronized and harvested 6–8 h after release) cells are
shown above representative histograms. The delay in cell cycle progres-
sion seen in these cells was corroborated by significantly lower fold
changes in Cyclin E protein in shB1 Clone-1 cells before and after star-
vation compared to control cells. No difference in Rb phosphorylation
was observed. Scr refers to control cells transfected with the scrambled
plasmid, C1 refers to shB1 Clone 1, C2 refers to shB1 Clone 2, CO refers
to cells only
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3.4 AKR1B1 expression enhances and AKR1B10 inhibits
NF-κB activity
Previously, tumors have been described as unhealed wounds
that recruit a vast number of inflammatory cells that can pro-
vide a microenvironment that is conducive for further prolif-
eration and metastasis [28]. To assess whether the altered
motilities observed in the presence of AKR1B1 or
AKR1B10 expression are also accompanied by alterations
in inflammation, we performed a GSEA for CRC samples
exhibiting the highest and lowest 30% AKR1B1 expression
levels, using the GSE39582 dataset [22]. A highly significant
(p < 0.001) enrichment was observed for the GO term
BREGULATION_OF_CYTOKINE_PRODUCTION^ in tu-
mors with a high AKR1B1 expression (Fig. 4A; for the full
set of genes for this GO term, see Supplementary Table 2).
On the other hand, we found that samples exhibiting the
highest 30% AKR1B10 expression did not show a significant
enrichment of any GO terms related to inflammation.
Using RNA-seq data from the TCGA portal for primary
CRC samples from 132 patients, we next carried out a
Spearman correlation analysis between the expression of
AKR1B1 or AKR1B10 and a set of 16 pro-inflammatory genes.
We found that AKR1B1 expression was positively correlated
with 10 of the 16 genes, whereas the expression of AKR1B10
was positively correlated with only 3 of the genes (Fig. 4B).
Strikingly, no common gene could be identified that was signif-
icantly correlated with both AKR1B1 and AKR1B10.
In order to subsequently determine whether inflamma-
tory signaling was altered in the cellular models used in the
current study, we examined the activation of nuclear factor
kappa B (NF-κB). NF-κB is a transcription factor that en-
hances the expression of pro-inflammatory genes such as
cytokines, chemokines, adhesion molecules and other im-
munoregulatory mediators [29]. Nuclear translocation of
NF-κB is associated with its transcriptional activation
[30]. Nuclear fractions of cell lysates from stably
AKR1B1 silenced HCT-116 cells or exogenously
AKR1B10 overexpressing HCT-116 cells showed a re-
duced translocation of the NF-κB subunits p65 and p50
from the cytoplasm to the nucleus (Fig. 4C). Moreover,
when we overexpressed AKR1B1 in AKR1B1-silenced
HCT-116 cells, we observed a partial rescue in the nuclear
translocation of p65 and p50 (Supplementary Fig. 4A).
Additionally, we found a reduced NF-κB activation in lu-
ciferase reporter assays when AKR1B1 was silenced in
HCT-116 cells. Exogenous overexpression of AKR1B1 in
LoVo cells reversed this effect (Fig. 4D). On the contrary,
we found that exogenous overexpression of AKR1B10 re-
sulted in a reduced transcriptional activity of NF-κB in
HCT-116 and LoVo cells (Fig. 4E). To further comprehend
the mechanism underlying enhanced NF-κB activation, we
examined ROS production in the context of AKR1B1 or
AKR1B10 expression. We found that AKR1B1 silencing
resulted in a significantly lower amount of ROS formation
(Supplementary Fig. 4B), whereas no change in ROS pro-
duction was observed when AKR1B10 was exogenously
overexpressed, indicating that for this other mechanisms
must be at work (data not shown).
3.5 High AKR1B1 expression correlates with a poor
prognosis and high AKR1B10 expression correlates
with a good prognosis in CRC patients
We next queried whether the expression of AKR1B1 and
AKR1B10 had any prognostic significance by analyzing the
GSE39582 dataset [22]. Log-Rank tests were performed be-
tween two groups of patients stratified by all possible thresh-
old values for each gene. The cut-off values that were within
the 25–75 percentiles with the lowest p values were selected
for further Kaplan-Meier analyses. By doing so, we found that
a high AKR1B1 expression was associated with a shorter
disease-free survival (DFS), while a high AKR1B10 expres-
sion was significantly associated with a longer DFS (Fig. 5A
and B). Although we did not observe any statistically signif-
icant difference in AKR1B1 expression across different CRC
stages in the GSE36582 set, the same dataset showed that a
high AKR1B1 expression was associated with a shorter DFS
in stage 2, 3 and 4 CRC (Supplementary Fig. 5).
To determinewhether AKR1B1 and/or AKR1B10may serve
as prognostic indicators for overall CRC survival, we performed
an independentmultivariate Cox proportional hazards regression
analysis (MVA), which revealed that this was indeed the case
(Fig. 5C). Based on these observations, we generated a com-
bined AKR gene signature for prognosis prediction, where
AKR1B10-high and AKR1B1-low patients were classified as
those with a Bgood^ prognosis, AKR1B1-high and
AKR1B10-low patients as those with a Bbad^ prognosis, and
the rest as those with an Bintermediate^ prognosis (Fig. 5D).
This classification generated a highly significant prognostic strat-
ification with a log rank p value < 0.001 (Fig. 5D). An additional
MVA that included clinicopathological parameters revealed that
the combined AKR gene signature was associated with disease-
free survival independent of age, gender, KRAS or BRAF muta-
tions, and TNM stage (Supplementary Table 4).
4 Discussion
The aldo-keto reductasesAKR1B1 andAKR1B10 exhibit a high
degree of similarity in amino acid sequence and structure and are
able to reduce a number of common substrates [31]. However,
AKR1B1 is ubiquitously expressed while the expression of
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AKR1B10 is restricted to the gut and adrenal glands. Therefore,
based on their distinct expression patterns, we hypothesized that
AKR1B1 and AKR1B10 may play distinct roles in CRC. Here,
we aimed to systematically test this hypothesis.
To this end, we first examined the expression of AKR1B1
and AKR1B10 in CRC tissues. Microarray and qRT-PCR-
based data indicated that the expression of AKR1B1 was
similar in CRC and normal tissues whereas the expression of
AKR1B10 was significantly reduced in the CRC samples,
particularly in Stages III and IV. AKR1B10 has been reported
to be a downstream target of p53. Therefore, loss of p53 ac-
tivity may be implicated in loss of AKR1B10 expression [15].
However, p53 inactivation is not a universal phenomenon in
CRC. Downregulation of AKR1B10 through promoter
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hypermethylation can also be ruled out since no CpG islands
could be identified in the AKR1B10 promoter [15].Moreover,
using a cohort of 295 CRC samples present in the TCGA data
set for which both methylation and expression information
was available, we found that DNA methylation and RNA
expression of AKR1B1were significantly negatively correlat-
ed (rank of 143 among 201 genes with Bonferroni corrected p
value < 0.01, r value < −0.70) while AKR1B10 was not found
to be significantly correlated (S.D., A.O.G., S.B., unpublished
data). Others have reported that in a cohort of 502 CRC cases,
70% of the tumors showed AKR1B1 promoter hypermethy-
lation with similar levels of hypermethylation in both adeno-
mas and carcinomas [32]. However, these authors also report-
ed that re-expression of AKR1B1 was not observed in a
DNMT (DNA Methyl Transferase) null CRC-derived cell
line, thereby underscoring the complex regulation of
AKR1B1 expression in CRC [32]. Hypermethylation of the
AKR1B1 promoter is not restricted to CRC and has also been
reported in e.g. breast cancer [33].
We found that AKR1B1 silenced cells showed a signifi-
cantly reduced proliferation, without affecting apoptosis. We
also observed downregulation of the mitogenic ERK1/2 pro-
teins [34] in AKR1B1 silenced cells, which may underlie the
reduced proliferation rate. Additionally, we found that a
slowed down cell cycle may have contributed to the reduced
proliferation rate of AKR1B1 silenced cells. Treatment of
growth factor stimulated CRC-derived cells with the aldo-
keto reducatse inhibitor sorbinil has been shown to induce
G1 arrest through downregulation of G1 cyclins and a reduced
activity of the transcription factor E2F [35]. In the current
study, we found that 6–8 h after release from starvation-
induced synchronization, a significantly larger proportion of
AKR1B1 silenced cells was still in the G1 phase, whereas
non-silenced control cells had already moved to the S phase.
We also found that the control cells exhibited increased Cyclin
E levels 6–8 h after release from starvation, as would be ex-
pected for cycling cells [36]. The increase in Cyclin E levels in
the AKR1B1 silenced cells 6–8 h after release from starvation
was significantly lower. This increase most likely reflects the
greater accumulation of these cells in the G1 phase. Of note,
we found that AKR1B1 silenced cells in general expressed
higher levels of Cyclin E, irrespective of whether the cells
were synchronized, starved or not. This was unlikely due to
transcriptional upregulation as we did not observe any chang-
es in the phosphorylation of Rb. Future studies are required to
elucidate the mechanism underlying the high Cyclin E protein
levels in AKR1B1 silenced cells. Interestingly, we found that
alterations in chromosome segregation and cell cycle regula-
tion were among the gene ontology terms that were enriched
(albeit non significantly, p = 0.057) in the GSEA of tumors
that expressed low amounts of AKR1B1. Overexpression of
AKR1B10 in HCT-116 cells did not result in any alteration in
proliferation, apoptosis or cell cycle progression. AKR1B10
has been reported to metabolize cytotoxic carbonyl com-
pounds to harmless intermediates [16]. Loss of AKR1B10
expression in CRC tissues may hamper the protection of these
tissues fromDNAdamage by carbonyl compounds. It remains
to be examinedwhether AKR1B10 overexpression can lead to
alterations in cell cycle arrest in CRC cells with DNA damage.
Pharmaceutical inhibition of AKR1B1 in HT-29 cells has
been shown to reduce growth factor-mediated adhesion to
endothelial cells and expression of cell adhesion molecules
[37]. These data were further supported by a reduced hepatic
metastasis of KM20 cells in nude mice to which AKR inhib-
itors were administered [37]. Additionally, it has recently been
found that AKR1B1may serve as a target of the mesenchymal
transcription factor Twist2 and as a major inducer of epithelial
to mesenchymal transition in basal-like breast carcinomas
[38]. Our analysis of CRC microarray-based expression data
(GSEA), TCPA as well as functional studies on CRC-derived
cell lines support the notion that high AKR1B1 levels may
result in enhanced motility and migration. Conversely, we
found that exogenous overexpression of AKR1B10 in HCT-
116 cells resulted in a significantly slower cell motility. The
role of AKR1B10 in metastasis appears to be highly context
dependent. In breast cancer, AKR1B10 has been reported to
be significantly associated with metastasis [39] through up-
regulation of integrin α5 and δ-catenin [40] whereas, similar
to our data, AKR1B10 overexpression in a nasopharyngeal
carcinoma-derived cell line was found to result in a slower
proliferation and a slower migration [41]. These differences
may, at least partly, be explained by the different cell types
Fig. 3 Effect of AKR1B1 and AKR1B10 expression on the
metastatic behavior of CRC cells. (A). GSEA showing a high
enrichment score (ES) of the Gene Ontology term CELL_
SUBSTRATE_ JUNCTION in patients from the GSE39582 data set
exhibiting the highest and lowest 30% AKR1B1 expression levels. The
plot reflects the degree to which a gene set is overrepresented at the top or
bottom of a ranked list of genes. The score at the peak of the plot (the
score farthest from 0.0) is the ES for the gene set. The position of indi-
vidual members of the gene set in the ranked list is indicated by vertical
lines. (B). TCPA data showing significantly higher expression levels of
the mesenchymal/motility markers collagen VI (p = 0.0003), fibronectin
(p = 0.0002), and transglutaminase (p = 0.0019) and a low expression of
claudin-7 (p = 0.0011) and FOXO 3a (p = 0.005) in the high 30%
AKR1B1 expressing samples versus the low 30% expressing samples.
(C). Wound healing assay showing a significantly slower wound closure
indicating a lower motility in stably AKR1B1 silenced HCT-116 cells.
Statistical analyses were carried out using ANOVA and Tukey’s posthoc
test, *p < 0.05, **p < 0.01. The cells were treated with mitomycin C
(0.5 μM) during the experiment to inhibit cell proliferation. (D).
Transwell migration assay showing a slower migration of HCT-116 cells
in which AKR1B1 was either silenced or AKR1B10 was overexpressed.
Statistical analyses were carried out using Student’s t-test, *p < 0.05,
****p < 0.0001. (E). Sirius Red assay showing less collagen deposition
(less red color) in AKR1B1 silenced in HCT-116 cells. (F). Hanging drop
assay showing a weaker cell-cell adhesion (less tight and well-formed
aggregates) in a dose-dependent manner when HCT-116 cells were
transfected with increasing amounts of the AKR1B1 overexpression
(o/ex) plasmid
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examined. The CRC-derived cell line HCT-8 has been found
to transition from an epithelial (E) phenotype to a rare more
rounded (R) highly metastatic phenotype when grown
(20 days) on soft substrates [42]. The ‘R’ cells expressed sig-
nificantly higher amounts of AKR1B10 than the ‘E’ cells.
Thus, AKR1B10 expression may generally be reduced in ep-
ithelial type CRC cells that predominate in most of the models
used to date. Interestingly, it has been found that epithelial
type MCF-7 breast cancer-derived cells overexpressing
AKR1B10 did not metastasize to lungs in vivo, whereas
MDA-MB-231 cells that are more mesenchymal in nature
[43] metastasized to the lungs when overexpressing
AKR1B10 [40]. It remains to be seen whether primary CRC
stem cells express higher amounts of AKR1B10 and whether
this influences the metastatic capability of these cells.
Fig. 4 Effect of AKR1B1 andAKR1B10 expression of inflammation.
(A). GSEA showing high enrichment scores (ES) of the Gene Ontology term
REGULATION_OF_CYTOKINE_ PRODUCTION in cases from the
GSE39582 data set with the highest 30% AKR1B1 expression compared
to the lowest 30%. The score at the peak of the plot (the score farthest from
0.0) is the ES for the gene set. The position of individual members of the gene
set in the ranked list is indicated by vertical lines. (B). Using the CoadRead
TCGA RNA-sequencing data, we tested whether 16 genes associated with
inflammation correlated with either AKR1B1 or AKR1B10 in the same
patients. A non-overlapping correlation of AKR1B1 and AKR1B10 was
observed for several pro-inflammatory markers. Asterisks represent samples
that are significantly correlated. Correlation r valuesweremarked from lowest
(blue) to highest (red). (C). Western blot showing reduced nuclear transloca-
tion of NF-κB in stably AKR1B1 silenced and AKR1B10 overexpressing
HCT-116. TopoII-βwas used as a loading control. Numbers under the bands
indicate band intensities normalized to the loading control. (D). Luciferase
assay showing reduced NF-κB transcriptional activity in stably AKR1B1
silenced HCT-116 cells. Overexpression of AKR1B1 in LoVo cells resulted
in enhanced transcriptional activity. Exogenous AKR1B10 overexpression in
both HCT-116 and LoVo cells resulted in reduced NF-κB transcriptional
activity. Statistical analyses were carried out using Students t-test.
*p < 0.05, ***p < 0.001
Fig. 5 AKR1B1 and AKR1B10 expression as prognostic CRC
markers. (A). LRMC plots for AKR1B1 and AKR1B10 showing
p values from Log-Rank tests performed between these two groups stratified
at each expression threshold value. Blue and red colors were used to indicate
association of gene expression with a good or poor prognosis, respectively.
The horizontal dotted line corresponds to the significance threshold of 0.05.
Vertical lines correspond to expression thresholds of the 25th, 50th and 75th
percentiles of patients. (B). Kaplan-Meier plots using patient data from the
GSE39582 set based on cut-off levels within the 25-75th percentiles with the
lowest p value for either AKR1B1 and AKR1B10 showed that high expres-
sion was significantly associated with shorter and longer disease-free survival
rates for AKR1B1 and AKR1B10, respectively. (C). Multivariate Cox pro-
portional hazards regression analyses with cut-offs in the 25-75th percentiles
with the lowest p valuewere used for both genes, showing that the prognostic
associations of AKR1B1 and AK1B10 were independent of each other. (D).
AnAKR1B1 andAKR1B10 combined gene signature (AKR) can predict the
prognosis of patients in the GSE39582 data set
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Activation of the polyol pathway can lead to the devel-
opment of oxidative stress which, in turn, can enhance the
activation of inflammatory transcription factors such as
NF-κB and AP-1 [8]. Pharmacological inhibition of
AKR1B1 has been shown to reduce NF-κB activity in
growth factor stimulated Caco-2 cells [11]. In support of
these data, we found that exogenous AKR1B1 overex-
pression or silencing in CRC-derived cells was directly
correlated with NF-κB activation, most likely through en-
hanced ROS production. No additional stimulation with
growth factors was necessary to observe these effects.
On the contrary, we found that exogenous AKR1B10
overexpression led to a reduced activation of NF-κB.
According to TCGA CoadRead RNA-seq data, the ex-
pression of a number of distinct non-overlapping sets of
inflammatory genes correlated with the expression of
AKR1B1 or AKR1B10. We found that AKR1B1 was pos-
itively correlated with several pro-inflammatory genes.
Among the genes that were positively correlated with
the expression of AKR1B10, the highest positive correla-
tion was observed for IL1-R2, a negative regulator of
interleukin (IL)-1 that binds with high affinity to IL-1β
and IL-1α, but does not induce any downstream signaling
[44]. Interestingly, the expression of IL-1α was also
found to be significantly positively correlated with
AKR1B10, indicating the possibility of negative feedback
mechanisms. While it is premature to conclude that
AKR1B10 has anti-inflammatory properties, it is likely
that the types of inflammation induced by AKR1B1 and
AKR1B10 serve different purposes.
The prognostic significances of AKR1B1 and AKR1B10
individually have been reported for several different tumor
types [15, 41, 45–47]. In CRC we found that the expression
of AKR1B1was not altered in cancer cells compared to normal
cells, both in silico and in in vitro experiments. This observa-
tion is supported by another study in which no significant dif-
ference was observed in AKR1B1 expression in CRC, normal
colon and ulcerative colitis tissue samples [48]. On the other
hand, current and other studies [8, 10, 35, 49] indicate that
AKR1B1 overexpression may be associated with alterations
in proliferation, cell cycle progression and the activation of
inflammatory pathways. AKR1B1 may also serve as a prog-
nostic CRCmarker since patients with a high AKR1B1 expres-
sion in the GSE39582 dataset showed a significantly shorter
disease-free survival (DFS). We found that this notion was also
supported by a lack of significant differences in the expression
of AKR1B1 using qRT-PCR (TissueScan CRC patient cDNA
array) on the basis of available TNM staging, node positivity
and differentiation information (data not shown).
AKR1B10 expression is dependent on the site of tumor
origin, with a generally lower expression reported for tumors
of the head and neck, bladder, stomach and colon compared to
their normal counterparts [50]. Moreover, in hepatocellular
carcinoma (HCC), where AKR1B10 has been reported to be
strongly upregulated in Hepatitis B virus (HBV)-related tu-
mors [51] as well as in primary hepatocellular carcinomas
[46], AKR1B10 overexpressing patients have been found to
have a more favorable prognosis, a reduced tumor recurrence
and a longer survival [50, 51]. For CRC, a similar favorable
prognosis has been noted for AKR1B10 high expressing tu-
mors using three independent data sets [15]. We found that in
the AKR1B10 high expressing group in the GSE39582 data
set the corresponding patients also showed significantly lon-
ger disease-free survival rates. Importantly, we have shown
here for the first time that a combined signature of low
AKR1B1 and high AKR1B10 expression provides a better
prognostic stratification for CRC patients compared to either
gene alone, and that this stratification is independent of other
confounding factors such as age, TNM stage and KRAS or
BRAF gene mutations.
5 Conclusions
In the current study we have shown that the functional effects
of alterations in AKR1B1 and AKR1B10 expression in CRC
are highly divergent even though both proteins catalyze very
similar reactions. Opposite effects were observed on cellular
proliferation, cell cycle progression, cellular motility and ac-
tivation of inflammatory signaling pathways. Intriguingly, we
found that differences in expression and role in inflammation
were also observed in patient datasets stratified according to
low or high AKR1B1 and AKR1B10 expression. Patients
with a high AKR1B10 expression had a more favorable prog-
nosis and GSEA showed that cells from these patients
expressed genes that were highly enriched in metabolic pro-
cesses, as would be expected for an enzyme that has a reduc-
tase function. On the other hand, we found that in AKR1B1
overexpressing patients, who had a worse prognosis, the cells
showed an enrichment in inflammatory signaling and cell-cell
adhesion. This dichotomy is interesting and implies that over-
expression of AKR1B1 in CRCmay lead to a loss or alteration
in its enzymatic function, causing the activation of additional
mitogenic signaling processes. This dichotomy is also
reflected by a combined gene expression signature where
low AKR1B1 and high AKR1B10 expression reflect a better
prognostic prediction than the individual genes alone. Future
studies are required to establish whether therapeutic targeting
of AKR1B1 will yield beneficial effects in CRC.
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